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Abstract
Current therapies for neurodegenerative diseases offer only limited benefits 
to their clinical symptoms and do not prevent the degeneration of neuronal cells. 
Neurological diseases affect millions of people around the world, and the economic 
impact of treatment is high, given that health care resources are scarce. Thus, many 
therapeutic strategies to delay or prevent neurodegeneration have been the subject 
of research for treatment. One strategy for this is the use of herbal and essential 
oils of different species of medicinal plants because they have several bioactive 
compounds and phytochemicals with neuroprotective capacity. In addition, they 
respond positively to neurological disorders, such as dementia, oxidative stress, 
anxiety, cerebral ischemia, and oxidative toxicity, suggesting their use as comple-
mentary treatment agents in the treatment of neurological disorders.
Keywords: neuroprotection, herbal medicines, neurological disorders,  
oxidative stress
1. Introduction
A number of complementary treatment are currently being investigated to 
provide neuroprotection or to treat neurodegenerative diseases. Some therapies 
are known to provide limited benefits because, despite their treating the clinical 
symptoms, they are not effective in preventing neuronal cell degeneration.
The economic impact of treating neurodegenerative disorders is also high with 
disproportionately scarce neurological services and resources that patient survival 
may depend on. Studies have shown that over 80% of natural deaths in low- and 
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middle-income countries may be attributed to stroke [1]. In the United States 
alone, the combined annual costs of neurological diseases total nearly $ 800 billion, 
expected to increase in the coming years due to an aging population, resulting in a 
severe economic burden to the health system [2].
Recent advances in understanding the pathophysiological mechanisms of neu-
rological disorders have led to new strategies in drug development. Animal models 
have contributed considerably to these advances, as they play an important role in 
evaluating potential drugs that can alleviate these conditions and also delay their 
processes [3].
Interest in natural products has increased significantly, resulting in the increas-
ing use of herbal medicines [4]. In a recent review, Izzo et al. report a 6.8% increase 
in US herbal and food supplement sales in 2014, with an estimated over $ 6.4 billion 
in total sales [5].
The clinical and social repercussions of neuropathologies reveal an important 
theme of study and commitment to structure strategies that can contribute to the 
quality of life of society. Scientific research has explored which stimuli and sub-
stances can contribute to neural cell plasticity, resulting in improved quality of life 
for people with depression, Alzheimer’s Disease (AD), Parkinson’s Disease (PD), 
among other nervous system-related disorders [6].
Increased neurogenesis and the facilitating effects of plasticity can be produced 
by a variety of treatments, including enriched environment, physical activity or 
drug action [7]. A complementary treatment proposed is the use of herbal medi-
cines, which have scientific relevance in the treatment of neurological diseases 
because they contain multiple compounds and phytochemicals that can have 
neuroprotective effect, with a consequent beneficial action for health in different 
neuropsychiatric and neurodegenerative disorders [8].
2. Neuroprotective effect of extracts
Studies have investigated therapies that can alleviate the symptoms of neuro-
degenerative disorders and also avoid the multiple pathogenic factors involved 
in these diseases. One promising approach is the use of herbal extracts and their 
isolated bioactive compounds for the treatment of conditions such as Parkinson’s, 
Alzheimer’s, cerebral ischemia. Behavioral analysis has shown them to have neuro-
chemical activity and symptom reduction [9].
Recent advances in understanding the pathophysiological mechanisms related to 
neurodegenerative diseases point to new strategies in drug development [10]. Animal 
models have contributed considerably to these advances and play an even greater role 
in evaluating possible drugs with therapeutic potential, not only to alleviate these 
pathologies, but also to modify the disease process [3]. Rodents are suitable models 
for these studies because of their well-characterized brain organization and the 
magnitude of information focused on altered states of the nervous system [11, 12].
Phytotherapics have scientific relevance in the treatment of neurological 
diseases, as they contain multiple compounds and phytochemicals that can have 
neuroprotective effects, with consequent beneficial health action between different 
neuropsychiatric and neurodegenerative disorders [8–10]. Several extracts that have 
shown beneficial action in these disorders as will be addressed in this paper.
2.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative pathology that results in pro-
gressive loss of cell function, structure and number, leading to widespread brain 
3Extracts and Essential Oils from Medicinal Plants and Their Neuroprotective Effect
DOI: http://dx.doi.org/10.5772/intechopen.90903
atrophy and profound cognitive and behavioral deficit [13]. Histopathologically, 
it is characterized by accumulation of beta-amyloid peptide (ßA), which can 
initiate a cascade of oxidative events and chronic inflammation leading to neuro-
nal death [14].
Several studies have investigated the action of Piper methysticum in experimen-
tal models of neurodegenerative diseases, specifically in AD, demonstrating the 
neuroprotective effect of this herbal medicine [15–17].
Piper methysticum is popularly known as Kava or Kava-kava, a perennial shrub 
belonging to the Pacific Ocean pepper family (Piperaceae) with historical and 
cultural significance is described in the literature as a compound that has neuropro-
tective action and anxiolytic effects and is used in sedatives, and analgesics, being 
anti-inflammatory, anticonvulsant and anti-ischemic. Most of these pharmacologi-
cal effects have been attributed to six kavalactones isolated from kava extracts, 
including yangonin, kawain and methysticin, dihydromethysticin, dihydrokavain 
and desmethoxyyangonin [18].
Recent studies, such as Fragoulis et al. have shown that one of the possible expla-
nations for the action of piper mechanism in AD is associated with the activation of 
the erythroid2-related nuclear factor (NrF2) [15].
Nrf2 is the major regulator of phase II detoxifying/antioxidant enzymes, 
including heme oxygenase 1 (HO-1). Transcription factor Nrf2 binds to ARE 
(antioxidant response element), transcribing a battery of genes involved in redox 
status, anti-inflammatory response and detoxification [19]. A study by Lobota et al. 
reports that Nrf2 activation and HO-1 induction are involved in the regulation of 
inflammation [20].
Another study developed to find agents that activate the Nrf2 factor was 
performed and three analytically pure kavalactones - Methysticin, Yangonin and 
Kavain - were researched. The effects of kavalactones on the protection of neural 
cells against beta-amyloid peptide (ßA)-induced neurotoxicity were evaluated 
using the ARE-luciferase and Western blot assay. The results indicated that kavalac-
tones Methysticin, Yangonin and Kavain activate time and dose-dependent Nrf2/
ARE in astroglial PC-12 and C6 neural C6 cells and thus up-regulate cytoprotective 
genes. At the same time, viability and cytotoxicity assays have shown that Nrf2 acti-
vation is able to protect neuronal cells from neurotoxicity by attenuating neuronal 
cell death caused by β amyloid [14].
Taken together, it is understood that the Nrf2/ARE signaling pathway is an 
attractive therapeutic target for neurodegenerative diseases and that chemically 
modified kavalactones as well as naturally occurring kavalactones can attenuate 
neurological damage by reducing oxidative stress and neuroinflammation.
Some herbal medicines have shown neuroprotective effects, such as curcumin, 
which is the main polyphenol found in turmeric (Curcuma longa), belonging to the 
Zingiberaceae family, native to South Asia and cultivated in the tropics [21]. It has 
been reported that this compound has properties that can prevent or ameliorate 
pathological processes related to neurodegenerative diseases such as cognitive 
decline, dementia and mood disorders [22]. In addition, curcumin has been investi-
gated for experimental models of treatment for Parkinson’s disease and has shown 
hopeful results [9].
Saffron compounds have been linked to beneficial biological properties such as 
anti-inflammatory, pro-apoptotic, antiproliferative, anti-amyloidogenic, antioxi-
dant, antiviral, and antidiabetic [23, 24]. Saffron’s most bioactive constituents are 
curcuminoids, including curcumin and its derivatives such as demethoxycurcumin 
and bisdemetoxycurcumin [25, 26].
The features attributed to curcumin, such as inhibition of amyloid pathology, 
protection against inflammation and oxidative stress, inhibition of beta amyloid 
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plaque aggregation and tau protein hyperphosphorylation, suggest that this com-
pound may prevent or improve pathological processes related to cognitive decline 
and dementia, as occur in the symptomatology of AD patients [27, 28].
A systematic review study showed that curcumin has a positive action on AD 
symptoms, both when assessing biochemical and behavioral symptoms. The 
proposed mechanisms of its action in AD show that it is able to act by preventing 
the formation and aggregation of β-amyloid protein and tau protein hispanphos-
phorylation [10], in addition curcumin has also been shown to prevent neural 
damage, mitochondrial disorders, cellular stress and glial hyperactivation, as shown 
in Figure 1.
Another compound that represents a promising approach is astragaloside IV 
(AS-IV), a triterpenoid saponin present in the root of Astragalus membranaceus 
(Fisch.) Bge. It is part of Chinese traditional culture [29], first described in the 
Chinese book Shen Nong Ben Cao Jing in 200 AD with a number of beneficial effects 
and no toxicity.
The biological and pharmacological properties of AS-IV include its protective 
effect on pathologies due to its wide range of beneficial actions, such as antioxidant, 
antibacterial, antiviral [30, 31], anti-inflammatory, anti-asthmatic, antidiabetic, 
antifibrotic, immunoregulatory and antimicrobial, and cardioprotective effects, pre-
venting myocardial insufficiency in rats [29–32], able to improve the immune system, 
digestion and promote wound healing [33].
Astragalus action can be understood based on the regulation of the release of 
caspases and cytochrome c (both being inducers of apoptosis), since cytochrome binds 
to Apaf-1 and Procaspase-9c when released into cytosol, forming a functional apopto-
some and subsequently triggering the sequential activation of caspase-3 and 9 [34]. 
Several stimuli that induce apoptosis, leading to the release of mitochondrial cyto-
chrome c which plays a key role in a common pathway of caspase activation [34, 35]. In 
addition, caspase-3 activation has been shown to be a fundamental step in the apoptosis 
process and its inhibition may block cellular apoptosis.
In addition, Chang et al. evaluated the action of AS-IV on the cerebral cortex 
after Aβ infusion, showing that i.p. Administration of 40 mg/kg/day of the herbal 
compound once daily for 14 days reduced the levels of mitochondrial dysfunction 
apoptosis in cortical cells blocked by inhibition of phosphoinositol 3-kinase (PI3K) 
protein kinase, known as AKT [36].
Figure 1. 
Active curcumin mechanisms after experimental treatment in AD models. Curcumin acts by preventing 
the formation and aggregation of β-amyloid protein and hyperphosphorylation of tau protein, stabilizing 
microtubules and preventing the formation of neurofibrillary tangles that occur due to deposition of this 
protein. It has also been shown to prevent mitochondrial damage favoring the increase of cellular ATP and 
the healthy maintenance of mitochondria, avoiding excessive Ca2+ intake. Curcumin is also able to counteract 
cellular stress and glial overactivation.
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The beneficial effects of AS-IV administration in experimental models of neu-
rodegenerative diseases proved to be effective in both in vivo and in vitro models, 
such as PD and AD, cerebral ischemia and encephalomyelitis by characterizing the 
antioxidant, antiapoptotic and anti-inflammatory action of this bioactive com-
pound on the various neurochemical substances and behavioral mechanisms. This 
suggests that the mechanisms presented by AS-IV offer a possible future comple-
mentary treatment for the potential treatment of these pathologies [10].
2.2 Parkinson’s disease
Parkinson’s disease (PD) is a condition that causes progressive neurodegenera-
tion of dopaminergic neurons with the consequent reduction of dopamine content 
in the substantia nigra. The 6-hydroxydopamine neurotoxin (6-OHDA) is widely 
used to mimic the neuropathology of PD [37].
There are reports in the literature analyzing the effect of supplementation, 
including Chinese herbs and herbal extracts that have shown clinical potential to 
attenuate the progression of PD in humans. In addition, plant extracts act on the 
neurochemical or motor profile in isolation [38]. It is known, however, that this 
pathology involves symptomatology related to both characteristics.
A recently published systematic review study discussed studies showing 
neuroprotective properties of medicinal plants and their bioactive compounds. 
These included Amburana cearenses (Amburoside A), Camellia sinensis (Catechins 
and Polyphenols), Gynostemma pentaphyllum (Saponin Extract), Pueraria lobata 
(Puerarin), Alpinia oxyphylla (Protocatechuic Acid), Cistanches salsa (Glycosides 
or Phenylethanoids), Spirulina platensis (Polysaccharide), and Astragalus 
Membranaceus - AS IV Tetracillic Saponin Triterpenoid [9].
As previously mentioned, Astragaloside showed a neuroprotective effect on 
several AD models. In addition, studies have shown the positive action of AS-IV in 
PD models. One of the studies induced Parkinson by the action of 6-OHDA, where 
AS IV attenuated the loss of dopaminergic neurons and the treated group presented 
intact germination, neurite growth and increased immunoreactive TH and NOS. In 
addition, when the pathology was induced in SH-SY5Y cell culture by MPP + (DP 
inducing drug) action, it also significantly reversed cell loss, nuclear condensation, 
intracellular generation of reactive oxygen species and pathway inhibition as medi-
ated by Bax; these effects, however, were related only to neurochemical analysis. 
Behavioral findings were not reported [39].
One legume that has become the target of scientific research for its neuroprotec-
tive properties is Mucuna pruriens. Behavioral analysis studies have been carried 
out with Mucuna pruriens (Alkaloids, coumarins, flavonoids, triterpenes, saponins, 
carotenoids) and Baicalein (Flavonoids) for PD, but no neurochemical evaluation 
has been performed. There are also publications demonstrating in vivo behavioral 
effects and in vitro neurochemical analyses, such as a recent publication showing 
the effect of Ligusticum officinale (Makino) on MPTP (1-methyl-4-phenyl-1,2,3,6)-
induced with an animal model and tetrahydropyridine, a neurotoxin capable of 
permanently causing symptoms of Parkinson’s disease by destroying the dopami-
nergic neurons of the substantia nigra. This drug has been used to study the disease 
in experiments with animals; the treatment restored behavior when compared to 
the control group. In this study, Withania somnifera (Ashwagandha) extract also 
showed improvement in all these physiological anomalies [9, 40–43].
Another study investigated the ability of guanosine to protect neuronal PC12 
cells from toxicity induced by 1-methyl-4-phenylpyridinium (MPP), the active 
metabolite of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), which 
mediates selective damage to dopaminergic neurons and causes irreversible 
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Parkinson-like symptoms in humans and primates. The results demonstrated 
that MPP-induced apoptosis of PC12 cells (cell line derived from a rat adrenal 
membrane pheochromocytoma) was significantly prevented by guanosine pretreat-
ment for 3 h. In addition, guanosine attenuated the collapse of the MPP-induced 
mitochondrial transmembrane potential and prevented subsequent activation of 
caspase-3, thus protecting dopaminergic neurons against mitochondrial stress-
induced damage [44].
Other studies have shown plants with neuroprotective properties capable of 
protecting from PD damage. These include plants such as Amburana Cearenses 
(Amburoside A) [5], Myracrodruon urundeuva (tannins and chalcones) [45], 
Camellia sinensis (catechins and polyphenols) [46], Gynostemma pentaphyllum 
(saponin extract) [47], Pueraria lobata (Puerarin) [48], Alpinia oxyphylla (proto-
catecholic citric acid) [49], parsley Cistanches salsa (phenylethane glycosides) [50, 
51], Spirulina platensis (polysaccharide) [22] and Astragalus membranaceus (triter-
penoid saponin), as mentioned in a review study [9, 39].
Current PD medications treat symptoms; none prevent or retard the degenera-
tion of dopaminergic neurons. It is understood that the above-mentioned herbal 
medicines have neuroprotective properties.
2.3 Neurological disorders/cerebrovascular diseases/brain dysfunctions
Stroke is the second leading cause of death in industrialized countries and the 
leading medical cause of acquired adult disability [52].
Piper methysticum is cited as a multi-potent phytopharmaceutical due to its 
numerous pharmacological effects including anxiolytic, sedative, anticonvulsant, 
anti-ischemic, local anesthetic, anti-inflammatory and analgesic activities. The use 
of Kava in brain dysfunctions has clinical and financial advantages, acting as an 
adjunct or complementary treatment to existing medications [53].
Chang et al. [9] have shown that the use of combined glucose and oxygen 
administration of guanosine (100 μM) significantly reduced the proportion of 
apoptosis. To determine whether guanosine was also neuroprotective in vivo, 
middle cerebral artery occlusion (CoA) was performed in male Wistar rats and 
guanosine (8 mg/kg) intraperitoneally or saline (control vehicle) was administered 
daily for 7 days. Guanosine prolongs survival and decreased neurological deficits 
and tissue damage resulting from CoA. These data are the first to demonstrate that 
guanosine is neuroprotective in stroke.
Through an experimental study developed by Backhauss and Krieglstein [55] 
that induced focal cerebral ischemia in rodents, through left middle cerebral artery 
(MCA) microbipolar coagulation, with the objective of evaluating whether kava 
extract and its constituents, kawain, dihydrokawain, Methysticin, dihydromethysti-
cin and yangonin, are capable of reducing the size of a heart attack zone in rats and 
mice, providing protection against ischemic brain damage. Compounds were admin-
istered ip, except kava extract, which was administered orally. The results demon-
strated that Kava extract decreased the infarct area in mouse brains and the infarct 
volume in rat brains. Methysticin and dihydromethysticin significantly reduced the 
infarct area in mouse brain, thus evidencing neuroprotective activity of the mice. 
Kava extract works by the action of its constituent’s methysticin and dihydromethys-
ticin. The other Kavapyronas could not produce a beneficial effect on the infarct area.
The study by Deng et al. examined whether late administration of GUO (guano-
sine) improved long-term functional recovery after stroke. Late administration of 
GUO improved functional recovery from day 14 after stroke when compared with 
the vehicle group [56].
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Gerbatin et al. evaluated the effect of guanosine on TBI-induced neurological 
damage. The findings showed that a single dose of guanosine (7.5 mg/kg), intraper-
itoneally (i.p) injected 40 min after fluid percussion injury (IPF) in rats protected 
them from locomotor and exploratory impairment, observed 8 h after injury, 
guanosine protected against neuronal death and activation of caspase 3 (protein 
responsible for cleaving genetic material.) This study suggests that guanosine 
plays a neuroprotective role in TBI and can be explored as a new pharmacological 
strategy [57].
Experimental models of ischemic stroke help our understanding of the events 
that occur in the ischemic and reperfused brain. One of the main developments in 
the treatment of acute ischemic stroke is neuroprotection.
2.4 Psychological disorders/anxiety/depression
Depression and stress-related disorders affect approximately 17% of the popu-
lation, resulting in enormous personal suffering as well as social and economic 
burdens [58].
Guanosine is a nucleoside that has a neuroprotective effect. Current studies have 
analyzed the action of guanosine as an antidepressant. One study investigated the 
effects of guanosine on the tail suspension test (TT), open field test and adult hip-
pocampal neurogenesis. The results suggest that the antidepressant effect of chronic 
guanosine use causes an increase in neuronal differentiation, suggesting that this 
nucleoside may be an endogenous mood modulator [59].
The ability of this nucleoside to nullify acute stress-induced behavioral and 
biochemical changes has not been evaluated in female mice, given that depression 
has a greater impact on women. A study aimed at investigating the protective effect 
of this nucleoside against oxidative damage and stress response evaluated this using 
the FST (forced swimming test). The Acute Containment Stress Protocol (ARS) 
has been proposed as a model that triggers biochemical changes in the rat brain that 
may be detrimental to CNS (central nervous system) function, implicated in several 
psychiatric disorders, including major depression [60].
Considering that the hippocampus plays a key role in mood regulation, numer-
ous studies have evaluated whether adult hippocampal neurogenesis is altered in 
psychiatric disorders. Stress is a risk factor for depression that can manifest itself 
years after the stressful event [54].
Behavioral studies have shown that guanosine produces anxiolytic substances 
and amnesic effects. Other analyses have shown that reductions induced by hip-
pocampal stress, cell proliferation and/or neuronal differentiation cause depressive 
symptoms. Deng et al. explain that hippocampal neurogenesis in humans is affected 
by various neurological disorders, including depression [56].
According to Duman et al. chronic administration of an antidepressant regulates 
neurogenesis in the hippocampus of adult rodents. Overregulation of neurogenesis 
could block or reverse the effects of stress on hippocampal neurons, which include 
downregulation of neurogenesis as well as atrophy. The possibility that the cAMP 
signal transduction cascade contributes to antidepressant regulation of neurogen-
esis is supported by previous studies and recent work [61].
Disturbances in hippocampal neurogenesis may be involved in the pathophysi-
ology of depression. It has been argued that an increase in the generation of new 
hippocampal nerve cells is involved in the mechanism of action of antidepressants. 
This study, using adult Wistar rats given fluoxetine, showed that a significant 
behavioral effect occurred. It also pointed out that chronic antidepressant treat-
ment increases cell proliferation as well as neurogenesis in the dentate gyrus. 
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Neurogenesis may serve as an important parameter for examining the efficacy and 
mechanism of action of new drugs [61].
Anxiety is a diffuse mental condition manifested through unpleasant feelings of 
fear and apprehension without specific cause [62].
Currently, the psychotherapeutic complementary treatment chosen to treat 
patients is through antidepressant drugs such as selective serotonin and serotonin-
norepinephrine reuptake inhibitors (SSRIs), tricyclic antidepressants and benzo-
diazepines [63]. Due to the undesirable and destructive side effects of these drugs, 
including drowsiness, cognitive impairment, and symptoms of dependence and 
withdrawal, many patients prefer herbal remedies. Several plants with anxiolytic 
activity have been studied in clinical trials, and Kava (Piper methysticum) has been 
shown to be effective and is mentioned as a nonadditive, nonhypnotic anxiolytic 
with phytotherapeutic potential to act as an adjuvant or complementary treatment 
to anxiolytic drugs [64, 65].
A meta-analysis review by Pittler et al. evaluated the efficacy and safety of kava 
extract versus placebo for treating anxiety. Seven randomized controlled trials using 
Piper methysticum indicated that kava extract is superior to placebo and relatively 
safe as a treatment option for anxiety [66].
Another recent meta-analysis, conducted by Ooi et al., revealed similar results, 
mentioning that there is promising evidence from well-designed clinical stud-
ies suggesting Kava, particularly aqueous extracts, as an effective treatment for 
generalized anxiety disorder (GAD) [67]. The authors add that the effect of Kava 
is comparable to commonly prescribed pharmacological drugs (buspirone and 
opipramol), but with fewer adverse consequences.
It is suggested that the progression of new treatments for psychological disorders 
is described in the identification of neural substrates and mechanisms underlying 
their etiology and pathophysiology. Adult hippocampal neurogenesis is a candi-
date mechanism for the etiology of depression and may be used as a substrate for 
antidepressant action, as it may also be important for some of the behavioral effects 
of antidepressants [68].
The therapeutic properties of kava are supported by the six major kavalactones 
(dihydromethysticin, kavain, dihydrokavain, methysticin, yangonin and desme-
thoxyyangonin), of which kawain and dihydrokawain have more intense anxiolytic 
activity [69].
3. Neuroprotective effect of essential oils
In recent years, growing interest in research on medicinal plants and the effects 
of essential oils (EOs), especially for the treatment of neuropathologies, has 
emerged [70]. EOs (also called volatile or ethereal oils) are odorous and volatile 
compounds found only in 10% of the plant kingdom [71–76].
Secondary metabolites present in SOs have been widely used as antibacte-
rial, antifungal and insecticidal agents. Their chemical and biological properties, 
especially antioxidants, have been considered important tools for the management 
of various neurological disorders [76].
Natural antioxidants derived from herbaceous plants have demonstrated in vitro 
cytoprotective properties and have a long history of providing benefits to human 
health [70]. Evidence of oxidative stress in neuronal damage and the benefits of 
antioxidant therapy have elucidated the importance of eliminating free radicals as 
a fundamental principle for the prevention and treatment of neurological disorders 
[77]. In addition, OEs derived antioxidants have been considered as a comple-
mentary treatment against neuronal loss as they have the ability to counteract the 
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activity of free radicals responsible for neurodegeneration [78], protecting against 
cellular stress, as outlined in Figure 2.
Neural cells suffer functional or sensory loss due to neurological disorders and, 
in addition to other environmental or genetic factors that contribute to this loss, oxi-
dative stress is a major contributor to neurodegeneration. Therefore, excess reactive 
Figure 2. 
Main identified mechanisms for the action of medicinal plant essential oils in experimental models of 
neurological disorders. In step A: In an experimental model of cerebral ischemia after occlusion of the common 
carotid artery followed by reperfusion (BCCAO/R), it was observed that occlusion in the frontal cortex caused 
a decrease in docosahexaenoic acid (DHA). with Pistacia lentiscus L. showing positive plasma levels in 
the proportion of DHA-for its precursor, eicosapentaenoic acid (EPA) and levels of palmitoylethanolamide 
(PEA) and oleoylethanolamine (OAS), reversing its reduction, consequently decreasing the susceptibility 
to oxidation. In step B: essential oils from different medicinal plants demonstrated positive effect on the 
cellular antioxidant system. Salvia lavandulifolia Vahl, Lavandula angustifolia SSP. mill and Lavandula 
hybrida acted by increasing the multiple enzyme system (Cat, SOD, GPX, GSH and GSSG), Salvia l. 
(GR) and propolis (SOD) after induction of oxidative stress induced by different oxidants. Salvia essential 
oil reduced the expression of malondialdehyde (MDA), a marker of lipid peroxidation, thus inhibiting 
effector caspase-3 by preventing cellular apoptosis and preventing mitochondrial damage. The essential oil 
of Lavandula angustifolia ssp. angustifolia Mill also potentiated the described antioxidant enzyme system, 
reversing the scopolamine-induced damage (simulating a dementia model) as well as decreasing MDA levels. 
Aloysia citrodora acted upon damage in an experimental model of H2O2 and B-amyloid induced AD and its 
ability to act on the antioxidant system was observed due to the ability of its compounds to act as free radical 
scavengers or hydrogen donors. Increasing the antioxidant defense system through the action of these essential 
oils assists in reducing hydrogen peroxide (H2O2) to H20 and O2. Essential oils from other medicinal plants 
also regulated MDA (Lavandula hybrida, Aloysia citrodora and Propolis) levels. In step C: Lavandula 
A. Mill. and Lavandula hybrida demonstrated effects on DNA fragmentation (cleavage patterns were 
absent in the treated groups suggesting their antiapoptotic activity), similar effects were also observed in Rosa 
damascena mill treatment. Which also slowed the oxidative degradation of DNA, lipids and proteins due 
to the presence of phenols in their composition. In step D: Aloysia citrodora essential oils acted on the cell 
membrane, helping to increase iron chelation in vitro through Fe3 + to Fe2 + hydroximation, an important 
mechanism because the transition metal ions contribute to the oxidative damage in Neurodegenerative 
disorders, thus the chelation of transition metals, prevent catalysis of hydrogen peroxide decomposition via 
Fenton-type reaction. L. angustifolia Mill, acting on MDA levels and in the formation of reactive oxygen 
species (ROS), which are oxidative markers, consequently also prevents lipid peroxidation (determined by 
MDA level) in rat temporal lobe homogenates. Pistacia lenticus also acts by attenuating the levels of the 
enzyme Cox-2 cyclooxygenase 2, consequently decreasing the inflammation and oxidative stress observed in 
untreated groups. In step E: The essential oils of S. lavandulifolia are capable of activating the transcription 
factor Nrf2 - Nuclear factor (erythroid-derived 2) -like 2, a regulator of antioxidant genes, since protein 
expression and enzyme activity CAT, SOD, GR, GPx and HO-1 is markedly reduced, correlating with a 
decrease in nuclear Nrf2 protein. After treatment with S. lavandulifolia, regulation of Nrf2 was identified 
with a concomitant increase in antioxidant enzymes and HO-1, avoiding the formation of ROS, oxidation 
and decreased cell viability.
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oxygen species and an unbalanced metabolism lead to a number of neurological 
disorders, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [78].
3.1 Alzheimer’s disease
Alzheimer’s disease (AD) is an age related neurodegenerative disease of the 
brain and this disease is characterized by a progressive deterioration of cognitive 
functions [79]. Oxidative stress, a detrimental factor during aging and pathologies, 
is involved in various neurodegenerative disorders [80, 81].
Studies suggest that caspase activation and apoptosis play important roles in 
AD neuropathogenesis [82]. Thus, SOs have been considered multi-potent agents 
against neurological disorders, being able to improve cognitive performance [83].
Lavender EO has several protective properties for the nervous system, as evi-
denced by its effectiveness in controlling depression, anxiety, stress, and cerebral 
ischemia [84, 85]. Some experimental models of AD have confirmed the neuropro-
tective effect and cognitive improvement of lavender OS, whose properties have 
been attributed to its antioxidant activity [86, 87].
EO (100 mg/kg) presented significant protection in the cognitive deficits 
evaluated, where the mechanism involved seems to be by a protection against 
decrease in the cellular antioxidant defense system, thus avoiding the reduction 
of the activity of superoxide dismutase, glutathione peroxidase and protection 
of the increase acetylcholinesterase malondialdehyde activity. The authors also 
demonstrated that lavender EO and its active component linalool protect against 
oxidative stress, cholinergic function and Nrf2/HO-1 pathway protein expression 
and synaptic plasticity. Therefore, it is suggested that linalool extracted from lav-
ender OS may be a potential agent for improving cognitive impairment, especially 
in AD [88].
3.2 Oxidative stress
Oxidative stress occurs when the balance between antioxidants and reactive 
oxygen species (ROS) occurs negatively due to the depletion of antioxidants or the 
accumulation of ROS (Reactive Oxygen Species) [89]. Hydrogen peroxide (H2O2) 
is a major ROS and is involved in most cellular oxidative stresses [90, 91]. Several 
plants are considered a rich source of antioxidants because they inhibit or retard 
ROS-induced oxidative degradation [92–94].
Porres-Martínez et al. demonstrated that Salvia lavandulifolia E.O has neu-
roprotective activity against H2O2-induced oxidative stress in PC12 cells [93]. 
These effects appear to be related to Salvia lavandulifolia EO’s ability to activate 
the transcription factor Nrf2. Therefore, pretreatments with S. lavandulifolia EO 
resulted in decreased lipid peroxidation, ROS levels and caspase-3 activity, showing 
cell viability and morphological recovery.
Natural antioxidants present in some herbal plants are responsible for inhibit-
ing or preventing oxidative stress, one of the agents that acts in AD, due to their 
ability to eliminate free radicals. The neuroprotective effect of A. citrodora has 
been attributed to its chelating activity. As described in the literature, an important 
mechanism of antioxidant effect is the chelation of transition metals, thus avoiding 
the catalysis of hydrogen peroxide decomposition via the Fenton type reaction [95]. 
The main proposed mechanisms regarding the action of A. citrodora and Salvia 
lavandulifolia OE in vitro models of neurological disorders.
A pioneering study by Abuhamdah et al. showed that Aloysia citrodora EO 
provides complete and partial protection from oxidative stress in an experimental 
model with H2O2-induced Alzheimer’s disease and β-amyloid-induced neurotoxicity 
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using neuroblastoma cells. This study showed that 250 μm H2O2 could not trigger its 
neurotoxic effect when in the presence of 0.01 and 0.001 mg/mL O. citrodora EO, 
exhibiting neuroprotective activity at both concentrations [70].
Chelating agents have been reported to be effective as secondary antioxidants 
because they reduce the redox potential of transition metals, thereby stabilizing 
the oxidized form of the metal ion [96]. This seems to be one of the mechanisms 
involved in the antioxidant activity of some essential oils, as some of them were able 
to effectively chelate iron (II).
3.3 Brain ischemia
Cerebral ischemia consists in decreased blood flow in specific areas of the brain, 
causing hypoxia, which leads to an insufficient supply of glucose and oxygen, the 
magnitude of which disturbs the development of normal brain functions [97].
Currently, treatments that minimize neuronal damage after cerebral ischemia 
are limited, thus leading to the search for new complementary treatment therapies 
[98]. Terpenoids present in some essential oils constitute the largest group of sec-
ondary metabolites with neurological properties, including sedative, antidepressant 
and antinociceptive activities [99].
Another metabolite with neuroprotective function is linalool, a monoterpene 
present in volatile lavender oil, responsible for important therapeutic properties 
[100]; its activity on nerve disorders is well documented [101, 102]. Vakili et al. 
demonstrated that Lavandula angustifolia had a protective effect on focal cere-
bral ischemia in Wistar rats, especially when the treatment was performed with 
Lavandula angustifolia EO at 200 and 400 mg/kg. The results of the administra-
tion of this EO were an avoidance of a total antioxidant defense, reduced cerebral 
edema, and reduced infarct size. In addition, it improved functional performance 
after cerebral ischemia [103].
4. Concluding remarks
Neurodegenerative and neuropsychiatric diseases have multiple etiology. 
Multiple studies have been developed to clarify which approaches might be promis-
ing in prevention and treatment. We have targeted studies that present a neuro-
protective perspective, herbal medicines and essential oils from different species 
of medicinal plants. These have various bioactive and phytochemical compounds 
with neuroprotective capacity, and also have given positive responses in studies on 
neurological disorders such as dementia, oxidative stress, anxiety, cerebral ischemia 
and oxidative toxicity. We suggest that these present a potential as agents in the 
treatment of neurological disorders.
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